Author

Chinmoy Bose

Deputy Editor in JMCR (Springer-Nature), Expert in CDSCO, Government of India. Oncologist in Netaji - Cited by 498 - Gynaecology - Obstetrics - Oncology - Virology - nonlinear dynamics.

Biography

Dr. Chinmoy Bose is an clinical gynecologist and consultant in clinical oncology. I am international peer in ovarian cancer. I do oncology drug development. Presently I am member in expert committee in drug regulatory authority of India. I am an examiner and paper setter in superspeciality DNB examination.
Title
Cited by
Year
Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy
A Mukhopadhyay, S Dasgupta, U Kanti Ray, F Gharami, CK Bose, ...Irish Journal of Medical Science (1971-) 184, 183-188, 2015201
34
2015
Determinants of lymph node status in women with breast cancer: A hospital based study from eastern India
A Chakraborty, CK Bose, J Basak, AN Sen, R Mishra, A MukhopadhyayThe Indian journal of medical research 143 (Suppl 1), S45, 2016201
19
2016
Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India
A Chakraborty, A Mukhopadhyay, D Bhattacharyya, CK Bose, ...Familial cancer 12, 489-495, 202
13
2013
Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
B Chinmoy KMedical Oncology 39 (47), https://doi.org/10.1007/s12032-022-01646, 20228202
8
2022
Anomalous endocrine feedback of peri-menopause in the etiology of type II ovarian cancer
CK BoseFuture Oncology 9 (9), 1257-121, 2013201
6
2013
Inhibitory role of a smart nano-trifattyglyceride of Moringa oleifera root in epithelial ovarian cancer, through attenuation of FSHR-c-Myc axis
A Ghosh, T Roychowdhury, R Nandi, R Maiti, NN Ghosh, SA Molla, ...Journal of Traditional and Complementary Medicine 11 (6), 81-92, 2021202
4
2021
Immune checkpoints, their control by immunotherapy and ovarian cancer
CK BoseContemporary Oncology/Współczesna Onkologia 21 (3), 189-196, 2017201
4
2017
Interplay of gut microbiome, fatty acids and the endocannabinoid system in regulating development, progression, immunomodulation and chemoresistance of cancer
SK Nandi, S Basu, A Bhattacharjya, RD Ghosh, CK Bose, ...Nutrition, 111787, 0
2
2022
Camostat in COVID-19
CK Bose, M BasuBiomedical Journal of Scientific & Technical Research 8 (1), 65-66, 000
2
2020
318P Antiproliferative effect of Moringaoleifera root extract on ovarian carcinoma: An in vitro study
A Ghosh, R Bhattacharya, C Pradhan, K Chaudhuri, A Mukhopadhyay, ...Annals of Oncology 7, ix99, 01601
2
2016
PARP inhibitors and more
CK Bose, N BasuJournal of the Turkish German Gynecological Association 16 (), 107, 01501
2
2015
Combined positive score (CPS) for scoring PD-L1 positivity
Combined positive score (CPS) for scoring PD-L positivityCK Bose, S MukhopadhyayCancer Research, Statistics, and Treatment 5 (4), 765-766, 2022202
1
2022
Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy
CK BoseMedical Oncology 39 (6), 67, 2022202
1
2022
siRNA and ovarian cancer
CK BoseIndian Journal of Gynecologic Oncology 9 (4), 85, 20220
1
2021
Debating cancer: The paradox in cancer research
A Mukhopadhyay, CK BoseThe Indian Journal of Medical Research 46 (3), 435, 20720
1
2017

Referred From: https://scholar.google.com/citations?user=LzAuS5AAAAAJ&hl=en

Cited by
Citations 498
h-index 12
i10-index 13
Open Access Journals